Humacyte (HUMA) Current Assets (2020 - 2026)

Humacyte (HUMA) has reported Current Assets for 7 consecutive years, with $92.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Current Assets rose 79.37% year-over-year to $92.8 million in Q2 2026; TTM through Jun 2026 was $92.8 million, a 79.37% increase from a year earlier, with the FY2025 full-year figure at $67.8 million, up 41.66% from the prior year.
• Current Assets was $92.8 million for Q2 2026 at Humacyte, up from $63.6 million in the prior quarter.
• Over five years, Current Assets peaked at $209.3 million in Q1 2022 and troughed at $23.0 million in Q3 2024.
• A 5-year average of $102.6 million and a median of $94.4 million in 2024 frame the typical range for Current Assets.
• Across the five-year window, Current Assets soared 41610.87% in 2022 and plunged 77.63% in 2024, its largest moves.
• Over 5 years, Current Assets stood at $154.2 million in 2022, then plunged by 46.0% to $83.3 million in 2023, then sank by 42.53% to $47.9 million in 2024, then soared by 41.66% to $67.8 million in 2025, then surged by 36.86% to $92.8 million in 2026.
• The last three Current Assets figures came in at $92.8 million (Q2 2026), $63.6 million (Q1 2026), and $67.8 million (Q4 2025), per Business Quant data.